Interactions of intestinal H+ oligopeptide cotransporter PEPT1 with drugs and regulation by affecting factors

Abstract

Abstract: H⁺ oligopeptide cotransporter PEPT1 mainly located at the brush border membrane of intestinal epithelium cell.transports dipeptide tripeptide which is the degradation products of protein in digestive tract. Peptide-like drugs such as β-lactam antibiotics, angiotensin-converting enzyme inhibitor (ACEI)and non-peptide drugs valaciclovir also can be transported and uptaked by PEPT1.PEPT1 is important for maintaining the homeostasis and the absorption of drugs in gastrointestinal tract.With the further research of PEPT1 gene, protein structure, and functional activity, we have known the factors about regulation of PEPT1 expression in membrane, their functional activities and substrate affinities.Some associated mechanism of regulation have been studied.As the wide substrate specificities of PEPT1, it becomes the target molecular on drug development and implication for drug delivery.Studies about interactions of PEPT1 with drugs are important for knowing the interactions of drugs, evaluating bioavailability of drug by intestinal absorption, researching the target treatment in anti-tumor drugs and individualization administration.

Key words: peptide transporter, PEPT1, interactions of drugs

CLC Number:

R966

ZHANG Qing-hao, LIU Ke-xin. Interactions of intestinal H⁺ oligopeptide cotransporter PEPT1 with drugs and regulation by affecting factors[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(3): 250-257.

References

1 Daniel H, Kottra G.The proton oligopeptide cotransporter family SLC15 in phy siology and pharmacology[J].Pflugers Arch, 2004;447:610-618.
2 Adibi SA.Renal assimilation of oligopeptide:physiological mechanisms and metabolic importance[J].Am J Physiol, 1997;272: E723-E736.
3 Hong L, Curtis K.Tissue distribution and thyroid hormone regulation of Pept1 and Pept2 mRNA in rodents[J].Peptides, 2006; 27:850-857.
4 Vivienne N, Yutao Y.Leptin transcriptionally enhances peptide transporter (hPepT1)expression and activity via the CREB and Cdx2 transcription factors[J].J Biol Chem, 2007;282:1359-1373.
5 Merlin D, Si-Tahar M.Colonic epithelial hPepT1 expression occurs in inflammatory bowel disease:transport of bacterial peptides influences expression of MHC class 1 molecules[J].Gastroenterology, 2001;120:1666-1679.
6 Kexin L, Yukio K, Kaku TI, et al.Hydroxyprolylserine derivatives JBP923 and JBP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats[J].J Pharmacol Exp Ther, 2000;294:510-515.
7 Stacey G, Koh S.Peptide transport in plants[J].Trends Plant Sci, 2002;7:257-263.
8 Urtti A, Johns SJ.Genomic structure of proton-coupled oligopeptide transporter hPEPT1 and pHsensing regulatory splice variant [J].AAPS Pharm Sci, 2001;3:E6
9 Saito H, Motohashi H.Cloning and characterization of a pHsensing regulatory factor that modulates transport activity of the human HC/peptide cotransporter, PEPT1[J].Biochem Biophys Res Commun, 1997;28:577-582.
10 Chen XZ, Steel A, Hediger MA.Functional roles of histidine and tyrosine residues in theHC-peptide transporter PepT1 [J]. Biochem Biophys Res Commun, 2000;16:726-730.
11 Watanabe C, Kato Y, Ito S, et al.Na⁺/H⁺ Exchanger 3 affects transport property of H⁺/Oligopeptide Transporter 1[J]. Drug Metab Pharmacokinet, 2005;20:443-451.
12 Thwaites DT, Kennedy DJ, Raldua D, et al.H⁺/dipeptide absorption across the human intestinal epithelium is controlled indirectly via a functional Na⁺/H⁺ exchanger[J].Gastroenterology, 2002, 122:1322-1333.
13 Sawada K, Terada T, Saito H, et al.Transport characteristics of basolateral peptide transporters betweenMDCK and Caco-2 cells [J].Pflugers Arch, 2001;443:31-37.
14 Leabman MK, Huang CC, DeYoung J, et al.Natural variation in human membrane transporter genes reveals evolutionary and functional costrains[J].Proc Natl Acad Sci USA, 2003;100: 5896-5901.
15 Zhang EY, Fu DJ, Pak YA, et al.Genetic polymorphisms in human proton-dependent dipeptide transporter PEPT1:implications for the functional role of Pro⁵⁸⁶ [J].J Pharmacol Exp Ther, 2004;310:437-445.
16 Anderle P, Nielsen CU, Pinsonneault J, et al.Genetic variants of the human dipeptide transporter PEPT1[J].Mol Pharm, 2004;1:300-308.
17 Buyse M, Berlioz F, Guilmeau S, et al.PepT1-mediated epithelial transport of dipeptides and cephalexin is enhanced by luminal leptin in the small intestine[J].J Clin Invest, 2001;108: 1483-1494.
18 ThamotharanM, Bawani SZ, Zhou X, et al.Hormonal regulation of oligopeptide transporter Pept-1 in a human intestinal cell line[J].Am J Physiol Cell Physiol, 1999;276:C821-C826.
19 Gangopadhyay A, ThamotharanM, Adibi SA.Regulation of oligopeptide transporter (Pept-1)in experimental diabetes[J].Am J Physiol Gastrointest Liver Physiol, 2002;283:G133-G138.
20 Kazuhiro W, Toshiya J, Juichi S.Effects of progesterone and norethisterone on cephalexin transport and peptide transporter PEPT1 expression in human intestinal cell line Caco-2[J].Biol Pharm Bull, 2006;29:90-95.
21 Li Q, Sai Y, Kato Y, et al.Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines[J].Pharm Res, 2003;20:1119-1124.
22 Ashida K, Katsura T, Motohashi H, et al.Thyroid hormone regulates the activity and expression of the peptide transporter PEPT1 in Caco-2 cells[J].Am J Physiol Gastrointest Liver Physiol, 2002;282:G617-G623.
23 Ashida K, Katsura T, Saito H, et al.Decreased activity and expression of intestinal oligopeptide transporter pept1 in rats with hyperthyroidism in vivo[J].Pharm Res, 2004;21:969-975.
24 Nielsen CU, Amstrup J, Steffansen B, et al.Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line[J].Am J Physiol Gastrointest Liver Physiol, 2001;281:G191-G199.
25 Nielsen CU, Amstrup J, Nielsen R, et al.Epidermal growth factor and insulin short term increase hPepT1 mediated glycylsarcosine uptake in Caco2 cells[J].Acta Physiol Scand, 2003; 178:139-148.
26 Buyse M, Charrier L, Sitaraman S, et al.Interferon-γIncreases hPepT1-mediated uptake of di-tripeptides including the bacterial tripeptide fMLP in polarized intestinal epithelia[J].Am J Clin Pathol, 2003;5:1969-1977.
27 Vavricka SR, Musch MW, Fujiya M, et al.Tumor necrosis factor-alpha and interferon-gamma increase PepT1 expression and activity in the human colon carcinoma cell line Caco-2 bbe and in mouse intestine[J].Pflugers Arch, 2006;452:71-80.
28 Thamotharan M, Bawani SZ, Zhou X, et al.Functional and molecular expression of intestinal oligopeptide transporter (Pept-1)after a brief fast[J].Metabolism, 1999;48:681-684.
29 Ihara T, Tsujikawa T, Fujiyama Y, et al.Regulation of PepT1 peptide transporter expression in the rat small intestine under malnourished conditions[J].Digestion, 2000;61:59-67.
30 Ogihara H, Suzuki T, Nagamachi Y, et al.Peptide transporter in the rat small intestine:ultrastructural localization and the effect of starvation and administration of amino acids[J].Histochem J, 1999;31:169-174.
31 Naruhashi K, Sai Y, Tamai I, et al.PepT1 mRNA expression is induced by starvation and its level correlates with absorptive transport of cefadroxil longitudinally in the rat intestine [J]. Pharm Res, 2002;19:1417-1423.
32 Shimakura J, Terada T, Saito H, et al.Induction of intestinal peptide transporter 1 expression during fasting is mediated via peroxisome proliferator-activated receptor alpha[J].Am J Physiol Gastrointest Liver Physiol, 2006;291:G851-G856.
33 Pan X, Terada T, Okuda M, et al.The diurnal rhythm of the intestinal transporters SGLT1 and PEPT1 is regulated by the feeding conditions in rats[J].J Nutr, 2004;134:2211-2215.
34 Okamura M, Terada T, Katsura T, et al.Inhibitory effect of zinc on PEPT1-mediated transport of glycylsarcosine and betalactam antibiotics in human intestinal cell line Caco-2[J]. Pharm Res, 2003;20:1389-1393.
35 Wenzel U, Kuntz S, Diestel S, et al.PEPT1-mediated cefixime uptake into human intestinal epithelial cells is increased by Ca²⁺ channel blockers [J].Antimicrob Agents Chemother, 2002;46:1375-1380.
36 Berlioz F, Julien S, Tsocas A, et al.Neural modulation of cephalexin intestinal absorption through the di-and tripeptide brush border transporter of rat jejunum in vivo[J].J Pharmacol Exp Ther, 1999;288:1037-1044.
37 Berlioz F, Maoret JJ, Paris H, et al.α₂-Adrenergic Receptors Stimulate Oligopeptide Transport in a Human Intestinal Cell Line[J].J Pharmacol Exp Ther, 2000;1294:466-472.
38 Tanaka H, Miyamoto KI, Morita K, et al.Regulation of the PepT1 peptide transporter in the rat small intestine in response to 5-fluorouracil-induced injury [J].Gastroenterology, 1998; 114:714-723.
39 Inoue M, Terada T, Okuda M, et al.Regulation of human peptide transporter 1 (PEPT1)in gastric cancer cells by anticancer drugs[J].Cancer Lett, 2005;230:72-80.
40 Hang CH, Shi JX, Sun BW, et al.Apoptosis and functional changes of dipeptide transporter (PepT1)in the rat small intestine after traumatic brain injury[J].J Surg Res, 2007;137:53-60.
41 Sundaram U, Wisel S, Coon S.Mechanism of inhibition of proton:dipeptide co-transport during chronic enteritis in the mammalian small intestine[J].Biochim Biophys Acta, 2005;1714: 134-140.
42 Shi B, Song D, Xue H, et al.PepT1 mediates colon damage by transporting fMLP in rats with bowel resection[J].J Surg Res, 2006;136:38-44.
43 Shi B, Song D, Xue H, et al.Abnormal expression of the peptide transporter PepT1 in the colon of massive bowel resection rat:a potential route for colonic mucosa damage by transport of fMLP[J].Dig Dis Sci, 2006;51:2087-2093.
44 Lardy H, Thomas M, Noordine Ml, et al.Changes induced in colonocytes by extensive intestinal resection in rats[J].Dig Dis Sci, 2006;51:326-332.
45 Shen H, Smith DE, Brosius FC 3rd.Developmental expression of PEPT1 and PEPT2 in rat small intestine, colon, and kidney [J].Pediatr Res, 2001;49:789-795.
46 Terada T, Inui K.Peptide transporters:structure, function, regulation and application for drug delivery [J].Curr Drug Metab, 2004;5:85-94.
47 Sai Y.Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition[J].Drug Metab Pharmacokinet, 2005;20:91-99.

[1]	LIU Zhaofeng, LI Ling, NA Shufang, YUE Jiang, YE Qifa. Regulation mechanism of post-translational modification of farnesoid X receptor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1292-1298.
[2]	YANG Li, BAI Huhu, HE Shasha, JIN Yue, LIU Chengsong. Tyrosine phosphorylation of TRPM3 ion channel mediates diabetes-induced heat hyperalgesia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 971-976.
[3]	LI Miao, YU Qinwei, JIANG Zhenzhou, ZHANG Luyong, . Regulatory mechanism of LDLR and research progress of its related diseases and drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 946-954.
[4]	CHEN Shengfu, LI Xiaolin, WANG Weigang, DU Weize, LI Maoxing. Research progress on antipyretic effect of Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 334-344.
[5]	. Research progress on ferroptosis regulators and their role in stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1320-1327.
[6]	LIU Chen, FANG Mengdie, XU Hao, LI Chao, REN Juan, ZUO Bowen, ZHANG Yanmei. Atractyloside targets the area of action of oncoprotein BORIS to inhibit cancer cell proliferation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1005-1013.
[7]	YANG Hechun, SHI Daohua . Research progress of small molecule inhibitors that reverse tumor drug resistance by regulating tumor glucose metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 836-840.
[8]	ZHANG Chenhan, NIE Jingyun, XIN Pengfei, CHAI Chen, LI Bo. Research progress of melatonin and pancreatic diseases#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1309-1314.
[9]	WANG Xiaoli, LU Shuping, DAI Jiale. Role of MSX2 in melanoma cells for trametinib resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1147-1154.
[10]	LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, YUE Jiang, WU Jianguo, YE Qifa. Relevance of CYP2R1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1053-1059.
[11]	ZHAO Li, HUA Xia, TAN Ye, HU Chenglian. Effects of sulforaphane-induced Akt/p70S6K signal transduction pathway on apoptosis of human nasopharyngeal cancer cells CNE-2 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 786-791.
[12]	QUAN Haiyan, LIU Yuhuan, YANG Li, YANG Fang, QIN Xuping. Improvement of CGRP on vascular endothelial cells insulin resistance via activation of cAMP/PPARγ/eNOS pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 615-622.
[13]	HAN Jinghong, LIU Yuchen, NIE Guohui. Transcriptomic analysis of neonatal mammalian vestibular after hair cell injury by neomycin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 481-489.
[14]	YAN Jieping，ZHANG Shuijun，ZHANG Guobing，HU Ying，LUO Dan，JIANG Hongjuan，LI Minjing. Protective effects of Butylphthalide on S-nitrosoglutathione-induced brain microvascular endothelial cells injury and potential mechanisms [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 517-522.
[15]	DING Qiuhua, SHI Daohua. Advances on the molecular mechanism of metformin's antitumor effect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 350-354.

Interactions of intestinal H⁺ oligopeptide cotransporter PEPT1 with drugs and regulation by affecting factors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments